# Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome

Study · id `cardio:ct-nct07770282` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07770282](<https://clinicaltrials.gov/study/NCT07770282>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07770282

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07770282. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2030-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07770282, source copy `cardio:ctgov-nct07770282-2026-08-18`, retrieved 2026-10-31)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07770282, source copy `cardio:ctgov-nct07770282-2026-08-18`, retrieved 2026-10-31)
- Primary completion: 2030-07-30 (anticipated) (ClinicalTrials.gov record NCT07770282, source copy `cardio:ctgov-nct07770282-2026-08-18`, retrieved 2026-10-31)
- Completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07770282, source copy `cardio:ctgov-nct07770282-2026-08-18`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07770282-2026-08-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
- Condition: Schizophrenia Disorder
- Condition: Metabolic Syndrome
- Condition: Antipsychotic-induced Weight Gain
- Condition: Cardiovascular Risk
- Condition: Insulin Resistance
- Intervention (Drug): Semaglutide + TAU
- Intervention (Drug): Placebo + TAU
- Lead sponsor: All India Institute of Medical Sciences, Bhubaneswar
- Lead sponsor class: OTHER
- Collaborator: Indian Council of Medical Research
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as the lead sponsor: All India Institute of Medical Sciences, Bhubaneswar (`cardio:org-all-india-institute-of-medical-sciences-bhubaneswar`)
- Registry lists this organization as a collaborator: Indian Council of Medical Research (`cardio:org-indian-council-of-medical-research`)

## Provenance

Content hash: da2404f718b97ed125fc7e6a54e9cf85abcc06624f0c3918e4c307833f23f8b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
